PA-PENNENGINEERING
PennEngineering® a global leader in innovative fastening solutions, has announced the expansion of its operations located in Galway City, Ireland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722804353/en/
(Photo: Business Wire)
This significant extension is set to create 70 new jobs over the next five years, in support of the company's commitment to growth and community development.
The €14 million expansion project, which involves the construction of a new building, includes a state-of-the-art technology and training centre as well as testing laboratories and customer experience centre that will enhance PennEngineering’s capacity to meet the increasing demand for engineering fastening solutions. The new jobs created will span a variety of roles, including manufacturing, engineering, training and more, offering diverse opportunities for local talent.
The expansion project is supported by the Irish Government through IDA Ireland.
Minister of State for Trade Promotion, Digital and Company Regulation, Dara Calleary TD said: “I am pleased to welcome this announcement from PennEngineering which will see the creation of 70 jobs as part of a major expansion project. Investments such as this continue to advance Galway’s position, in particular, as a global hub. I am pleased to welcome this announcement and wish PennEngineering every success.”
“We are thrilled to expand our operations in Galway,” said Mary Ann Fleming, President, PennEngineering Europe. “This investment reflects our confidence in the potential for growth in the region and our commitment to contributing to the local economy. We look forward to welcoming new members to our team and continuing to innovate in the world of fastening technology. Our on-site manufacturing also continues to expand with the introduction of new products, continuing our 82-year history of product innovation in self-clinch fasteners. Supporting training and development of our people and job creation are priorities for us, and this expansion is key to this initiative. As part of this growth announcement, we welcome the board of PennEngineering on site for their biannual meeting and wish them well as they strategise for the future of our global company.”
“Our long-standing partnership with Ireland and the IDA spans over 20 years, and their support has been invaluable in fostering the growth and development of our business in Europe,” according to Pete George, PennEngineering CEO.
The expansion is expected to be completed by January 2025. PennEngineering plans to begin the recruitment process immediately, with job openings to be posted on the company’s website and local job boards.
Mary Buckley, Executive Director of IDA Ireland, said: “PennEngineering has been in Galway since 2001, and this announcement today highlights their ongoing commitment to the West Region. The operation is already a recognised centre of excellence within the global organisation and this 4000m² expansion and 70 jobs further enhances its strategic capabilities in Galway. I wish the PennEngineering team continued success.”
For more information about the expansion and job opportunities, please visit www.pemnet.com/eu/.
About PennEngineering: https://www.penn-eng.com/
Since 1942, PennEngineering® has enjoyed a sustained reputation as the global leader in the fastening industry. The company's brands, PEM®, PROFIL®, Sherex®, PennAuto®, are considered the premier manufacturer for self clinching and other mechanically attached fasteners. Haeger®, for installation systems and Heyco® for molded and stamped products.
PennEngineering’s steadfast commitment to engineering expertise and global innovation ensures that we continue to grow our portfolio with technologies and solutions that allow our customers to not only keep pace with marketplace challenges – but exceed them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722804353/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom